Li Hongru, Xu Yadong, Li Hui
Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Reproductive Department, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Oncotarget. 2017 Jul 15;8(37):62573-62588. doi: 10.18632/oncotarget.19257. eCollection 2017 Sep 22.
To assess the prognostic and clinicopathological characteristics of CD147 in human bladder cancer.
Studies on CD147 expression in bladder cancer were retrieved from PubMed, EMBASE, the Cochrane Library, Web of Science, China National Knowledge Infrastructure, and the WanFang databases. Outcomes were pooled with meta-analyzing softwares RevMan 5.3 and STATA 14.0.
Twenty-four studies with 25 datasets demonstrated that CD147 expression was higher in bladder cancer than in non-cancer tissues (OR=43.64, P<0.00001). Moreover, this increase was associated with more advanced clinical stages (OR=73.89, P<0.0001), deeper invasion (OR=3.22, P<0.00001), lower histological differentiation (OR=4.54, P=0.0005), poorer overall survival (univariate analysis, HR=2.63, P<0.00001; multivariate analysis, HR=1.86, P=0.00036), disease specific survival (univariate analysis, HR=1.65, P=0.002), disease recurrence-free survival (univariate analysis, HR=2.78, P=0.001; multivariate analysis, HR=5.51, P=0.017), rate of recurrence (OR=1.91, P=0.0006), invasive depth (pT2∼T4 vs. pTa∼T1; OR=3.22, P<0.00001), and histological differentiation (low versus moderate-to-high; OR=4.54, P=0.0005). No difference was found among disease specific survival in multivariate analysis (P=0.067), lymph node metastasis (P=0.12), and sex (P=0.15).
CD147 could be a biomarker for early diagnosis, treatment, and prognosis of bladder cancer.
评估CD147在人膀胱癌中的预后及临床病理特征。
从PubMed、EMBASE、Cochrane图书馆、Web of Science、中国知网和万方数据库检索关于膀胱癌中CD147表达的研究。采用RevMan 5.3和STATA 14.0等荟萃分析软件汇总结果。
24项研究（共25个数据集）表明，膀胱癌中CD147的表达高于非癌组织（OR=43.64，P<0.00001）。此外，这种升高与更晚期的临床分期（OR=73.89，P<0.0001）、更深的浸润（OR=3.22，P<0.00001）、更低的组织学分化（OR=4.54，P=0.0005）、更差的总生存期（单因素分析，HR=2.63，P<0.00001；多因素分析，HR=1.86，P=0.00036）、疾病特异性生存期（单因素分析，HR=1.65，P=0.002）、无疾病复发生存期（单因素分析，HR=2.78，P=0.001；多因素分析，HR=5.51，P=0.017）、复发率（OR=1.91，P=0.0006）、浸润深度（pT2∼T4 对比 pTa∼T1；OR=3.22，P<0.00001）以及组织学分化（低分化对比中高分化；OR=4.54，P=0.0005）相关。多因素分析中疾病特异性生存期（P=0.067）、淋巴结转移（P=0.12）和性别（P=0.15）方面未发现差异。
CD147可能是膀胱癌早期诊断、治疗及预后的生物标志物。
